David Rose
Get 20% off your bill at Pizza Express
A treatment for brittle bones can have a dramatic effect on breast cancer when combined with chemotherapy, research has shown.
Scientists found that the two drugs acted together to slow down the growth of tumours. In mice given the therapy, growing breast tumours were almost stopped in their tracks.
A clinical trial is under way in the UK that could lead to the treatment becoming widely available to patients. Since both drugs are already well established, and need only the terms of their use to be changed, this may not take long, the researchers suggest.
The therapy involves the breast cancer chemotherapy agent doxorubicin and the bisphosphonate drug zoledronic acid.
In the mouse study, doxorubicin was given first, followed 24 hours later by zoledronic acid. When the order was reversed, or the drugs administered on their own, the treatment had little effect. The scientists said that the chemotherapy drug appeared to “prime” the tumour and make it sensitive to the bisphosphonate.
Tests showed that the treatment triggered a “suicide” response known as apoptosis in the cancer cells, causing them to self-destruct. It also blocked angiogenesis, the process by which blood vessels are created that fuel tumours with oxygen and nutrients.
The researchers, from the University of Sheffield and the University of Kuopio in Finland, published their findings in the Journal of the National Cancer Institute.
Bisphosphonates are normally used to prevent bone thinning in patients with osteoporosis. They also protect bones from the destructive effects of tumours. For this reason they are sometimes given to men with prostate cancer, which has a habit of spreading to the bones. The new study showed that zoledronic acid can have a powerful direct effect on breast cancer without any bone involvement.
The results of the clinical trial, led by Professor Robert Coleman, of the University of Sheffield, should be known this year.
Industry sectors news at a glance. Interactive heatmap, video and podcast
The inside track on current trends in the charity, not for profit and social enterprise sectors
Explore your passion for food with the delights of Thai, Indian & Chinese cooking
Read our exclusive 100 Years of Fleming and Bond interactive timeline, packed with original Times articles and reviews
Everything the Business Traveller needs to know to make a better trip
Shortcuts to help you find sections and articles
05/2005
£13,500
08/2008
£109,950
2006
£10,750
Great car insurance deals online
£100k
The National Skills Academy for Social Care
London
£49,229 - £62,035 pro rata
Charity Commission
London/Liverpool/Taunton
£75k - £85k
Confidential
London
Six Figure
Rolls Royce
Midlands/Europe
From £89,950
Great Investment, River Views
$3.5 million
Also avaliable for rent
Times Online Property Search will help you find it
Amazing Far East Offers - Visit Hong Kong
from £499pp
Cruise the Islands of Hawaii - Pride of America
List your property with two leading travel websites
Great travel insurance deals online
Contact our advertising team for advertising and sponsorship in Times Online, The Times and The Sunday Times, or place your advertisement.
Times Online Services: Dating | Jobs | Property Search | Used Cars | Holidays | Births, Marriages, Deaths
News International associated websites: Globrix | Property Finder | Milkround
Copyright 2008 Times Newspapers Ltd.
This service is provided on Times Newspapers' standard Terms and Conditions. Please read our Privacy Policy.To inquire about a licence to reproduce material from Times Online, The Times or The Sunday Times, click here.This website is published by a member of the News International Group. News International Limited, 1 Virginia St, London E98 1XY, is the holding company for the News International group and is registered in England No 81701. VAT number GB 243 8054 69.
Some reports are saying this is a 10th of the cost of Herceptin, but Herceptin is the only current treatment for Her2+ cancers diagnosed in 25% of patients. Bisphosphonates are already given to patients with bone secondaries, I think the drug is Zoladex.
Linda, Fife,